• Vaccine Name: Synthetic MUC1 Peptide Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004258
• Type: Subunit vaccine
• Status: Research
• Antigen: The 140-aa synthetic MUC1 peptide (Soares et al., 2001).
• MUC1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: This article lays out the relationship between MUC1 and tumor growth used in cancer vaccines. (Soares et al., 2001)
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001336
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: MUC1-Tg mice (4–6 wk old) on a C57BL/6 background
• Vaccination Protocol: Three different immunization protocols were tested in vivo. Mice were immunized with: 1) synthetic MUC1 peptide (100 µg/mouse) coadministered with soluble murine GM-CSF (2 µg/mouse; a generous gift from Immunex, Seattle, WA) injected s.c.; 2) synthetic MUC1 peptide (100 µg/mouse) coadministered with SB-AS2 (50 µl/mouse; a generous gift of SmithKline Beecham Biologicals, Rixensart, Belgium) injected i.m.; or 3) murine DC prepulsed with 20 µg/ml of synthetic MUC1 peptide in AIM-V medium (Life Technologies, Grand Island, NY) overnight (2–5 x 104 DC/mouse injected s.c.) (Soares et al., 2001).
• Challenge Protocol: Ten days after the last boost, the mice were anesthetized with Metofane (Schering-Plough Animal Health, Omaha, NE) and 5 x 10^4 RMA-MUC1 cells injected s.c. in the shaved right hind flank. Tumor growth was monitored every 2–3 days and tumor size determined with calipers (Soares et al., 2001).
• Efficacy: WT and MUC1-Tg mice that had been immunized with MUC1 peptide admixed with either GM-CSF or SB-AS2 also had to be sacrificed because they failed to reject the tumors (Soares et al., 2001).